Advances in the treatment of craving for alcohol and tobacco

Translation of Addictions Science Into Practice

Volumn , Issue , 2007, Pages 211-237

  Monti, Peter M ^a   MacKillop, James ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954234999     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008044927-2/50060-2     Document Type: Chapter

References (145)

1. Abrams, D.B., Monti P.M., Carey K.B., Pinto R.P., Jacobus S.I. Reactivity to smokingcues and relapse: Two studies of discriminant validity. Behaviour Research and Therapy 1988, 26:225-233.
2. Anderson J.E., Jorenby D.E., Scott W.J., Fiore M.C. Treating tobacco use and dependence: Am evidence-based clinical practice guideline for tobacco. Chest 2002, 121:932-941.
3. Anton R., Moak D., Latham P. The Obsessive-Compulsive Drinking Scale: A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcoholism: Clinical and Experimental Research 1995, 19:92-99.
4. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. American Journal of Psychiatry, Nov 1999, 156(11):1758-1764.
5. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interven- tions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association 2006, 295:17.
6. Baumann S.B., Sayette M.A. Smoking cues in a virtual world provoke craving in cigarette smokers. Psychology of Addictive Behaviors, 2006, 20:1-6.
7. Berrettini W.H., Lerman C.E. Pharmacotherapy and pharmacogenetics of nicotine dependence. American Journal of Psychiatry, 2005, 162:1441-1451.
8. Boothby L.A., Doering P.L. Acamprosate for the treatment of alcohol dependence. Clinical Therapeutics, 2005, 27:695-714.
9. Bordnick P.S., Graap K.M., Copp H., Brooks J., Ferrer M., Logue B. Utilizing virtual reality to standardize nicotine craving research: A pilot study. Addictive Behaviors, 2004, 29:1889-1894.
10. Bouton M.E., Bolles R.C. Contextual control of extinction of conditioned fear. Learning and Motivation, 1979, 10:445-466.
11. Bouton M.E., Brooks D.C. Time and context effects on performance in Pavlovian discrimination reversal. Journal of Experimental Psychology: Animal Behavior Processes, 1993, 19:165-179.
12. Bouton M.E., Swartzenruber D. Slow reacquisition following extinction: Context, retrieval, and encoding mechanisms. Journal of Experimental Psychology: Animal Behavior Processes 1989, 15:43-53.
13. Brandon T.H., Tiffany S.T., Obremski K.M., Baker T.B. Post cessation cigarette use: The process of relapse. Addictive Behaviors, 1990, 15:105-114.
14. Brooks D.C., Bouton M.E. A retrieval cue for extinction attenuates response recovery (renewal) caused by a return to the conditioning context. Journal of Experimental Psychology: Animal Behavior Processes, 1993, 20:366-379.
15. Virtual Reality Technology 2003, Wiley Interscience, Hoboken, NJ. 2nd ed. B. G. C., C. P. (Eds.).
16. Chelonis J.J., Calton J.L., Hart J.A., Schachtman T.R. Attenuation of the renewal effect by extinction in multiple contexts. Learning and Motivation 1999, 30:1-14.
17. Chick J., Anton R., Checinski K., Croop R., Drummond D.C., Farmer R., Labriola D., Marshall J., Moncrieff J., Morgan M.Y., Peters T., Ritson B. A multicentre, ran-domized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol depend-ence or abuse. Alcohol and Alcoholism 2000, 35(6):587-593.
18. Collins B.N., Brandon T.H. Effects of extinction context and retrieval cues on reactiv-ity among nonalcoholic drinkers. Journal of Consulting and Clinical Psychology 2002, 70:390-397.
19. Conklin C.A. Environments as cues to smoke: Implications for human extinction-based research and treatment. Experimental and Clinical Psychopharmacology 2006, 14(1):12-19.
20. Conklin C.A., Tiffany S.T. Applying extinction research and theory to cue-exposure addiction treatment. Addiction 2002, 97:155-167.
21. Corty E., McFall R.M. Response prevention in the treatment of cigarette smoking. Addictive Behaviors 1984, 9(4):405-408.
22. Cowen M.S., Adams C., Kraehenbuehl T., Vengeliene V., Lawrence A.J. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addiction Biology 2005, 10:233-242.
23. Czachowski C.L., Legg B.H., Samson H.H. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcoholis: Clinical and Experimental Research 2001, 25:344-350.
24. Davidson D., Palfai T., Bird C., Swift R. Effects of naltrexone on alcohol and self-administration in heavy drinkers. Alcoholism: Clinical and Experimental Research 1999, 23:195-203.
25. Davidson D., Swift R., Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcoholism: Clinical and Experimental Research 1996, 20:732-739.
26. Dawe S., Powell J.H., Richards D., Gossop M., Strang J., Gray J.A. Does post-withdrawal cue exposure improve outcome in opiate addiction? A controlled trial. Addiction, 1993, 88:1233-1245.
27. Dawe S., Rees V.W., Mattick R., Sitharthan T. Efficacy of moderation-oriented cue exposure for problem drinkers: A randomized controlled trial. Journal of Consulting and Clinical Psychology 2002, 70:1045-1050.
28. Deas D., May K., Randall C., Johnson N., Anton R. Naltrexone treatment of adolescent alcoholics: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology 2005, 15:723-728.
29. Denniston J.C., Chang R., Miller R.R. Massive extinction treatment attenuates the renewal effect. Learning and Motivation 2003, 34:68-86.
30. Doty P., de-Wit H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behavioural Pharmacology, 1995, 6:386-394.
31. Doty P., Kirk J.M., Cramblett M.J., de-Wit H. Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment. Drug and Alcohol Dependence 1997, 47:109-116.
32. Drummond D.C. Is cue exposure cure exposure?. Addiction 2002, 97:357-359.
33. Drummond D.C., Cooper T., Glautier S.P. Conditioned learning in alcohol depend-ence: Implications for cue exposure treatment. British Journal of Addiction 1990, 85:725-743.
34. Drummond D.C., Glautier S.T. A controlled trial of cue exposure treatment in alcohol dependence. Journal of Consulting and Clinical Psychology 1994, 62:809-817.
35. Erblich J., Bovbjerg D.H. In vivo versus imaginal smoking cue exposures: Is seeing believing?. Experimental and Clinical Psychopharmacology 2004, 12:208-215.
36. Fant R.V., Owen L.L., Henningfield J.E. Nicotine replacement therapy. Primary Care 1999, 26:633-652.
37. Fagerstrom K., Schneider N., Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology, 1993, 11:271-277.
38. Feinn R., Kranzler H.R. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?. Alcoholism: Clinical and Experimental Research 2005, 29:983-988.
39. Fiore M.C., Jorenby D.E., Baker T.B. Smoking cessation: Principles and practice based upon the AHCPR guideline, Agency for Health Care Policy and Research. Annals of Behavioral Medicine 1997, 19:213-219.
40. Foa E.B., Kozak M.J. Emotional processing of fear: Exposure to corrective information. Psychological Bulletin vn99 1986, (1):20-35.
41. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., Loewy J.W., Ehrich E.E. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. The Journal of the American Medical Association 2005, 293(13):1617-1625. for the Vivitrex Study Group.
42. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. Pharmacological treat-ment of alcohol dependence: A review of the evidence. Journal of the American Medical Association 1999, 281(14):1318-1325.
43. George T.P., O'Malley S.S. Current pharmacological treatments for nicotine depend-ence. Trends in Pharmacological Sciences 2004, 25(1):42-48.
44. Goldstein M.G. Pharmacotherapy for smoking cessation. The Tobacco Dependence Treatment Handbook: A Guide to best practices 2003, 230-249. Guilford Press, New York. D.B. Abrams, R. Niaura, R.A. Brown, K.M. Emmons, M.G. Goldstein, P.M. Monti (Eds.).
45. Gunther L.M., Denniston J.C., Miller R.R. Conducting exposure treatment in mul-tiple contexts can prevent relapse. Behavior Research and Therapy 1998, 36:75-91.
46. Harris J.A., Jones M.L., Bailey G.K., Westbrook G.F. Contextual control over con-ditioned responding in an extinction paradigm. Journal of Experimental Psychology: Animal Behavioral Processes, 2000, 26:174-185.
47. Harvey K., Kemps E., Tiggemann M. The nature of imagery processes underlying food cravings. British Journal of Health Psychology 2005, 10(1):49-56.
48. Havermans R.C., Keuker J., Lataster T., Jansen A. Contextual control of extinguished conditioned performance in humans. Learning and Motivation 2005, 36(1):1-19.
49. Heather N., Brodie J., Wale S., Wilkinson G., Luce A., Webb E., McCarthy S. A ran-domized controlled trial of moderation-oriented cue exposure. Journal of Studies on Alcohol 2000, 61(4):561-570.
50. Hernandez-Avila, C. A., Song, C., Kuo, L., Tennen, H., Armeli, S., Kranzler, H. R. Targeted ver- sus daily naltrexone: Secondary analysis of effects on averag.
51. Hutchison K.E., LaChance H., Niaura R., Bryan A., Smolen A. The DRD4 VNTR. polymorphism influences reactivity to smoking cues. Journal of Abnormal Psychology 2002, 134-143.
52. Hutchison K.E., McGeary J.E., Smolen A., Swift R.M., Bryan A. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychology 2002, 21:139-146.
53. Hutchison, K. E., Ray, L., Sandman, E., Rutter, M. C., Peters, A., Davidson, D., & Swift, R. (in press). The effect of olanzapine on craving and alcohol consu.
54. Hutchison K.E., Rutter M.C., Niaura R., Swift R.M., Pickworth W.B., Sobik L. Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology 2004, 175:407-413.
55. Hutchison K.E., Swift R.M., Rohsenow D.J., Monti P.M., Davidson D., Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 2001, (155):27-34.
56. Hutchison K.E., Wooden A., Swift R.M., Smolen A., McGeary J., Adler L., Paris L. Olanzapine reduces craving for alcohol: A DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003, (10):882-888. Oct,.
57. Jarvik M., Schneider N Nicotine. Substance Abuse: A Comprehensive Textbook 1992, 334-356. Baltimore, MD: Lippincott Williams & Wilkins. J. Lowinson, P. Ruiz, R. Millman (Eds.).
58. Johnson B.A., Ait-Daoud N., Aubin H.J., van den Brink W., Guzzetta R., Loewy J., Silverman B., Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol depen. Alcoholism: Clinical and Experimental Research 2004, 28(9):1356-1361.
59. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.R., Roache J.D., Lawson K., Javors M.A., Ma J.A. Oral topiramate for treatment of alcohol dependence: A randomized controlled trial. Lancet 2003, 361:1677-1685.
60. Kavanagh D.J., Andrade J., May J. Beating the urge: Implications of research into substance-related desires. Addictive Behaviors 2004, 29:1359-1372.
61. Kavanagh D.J., Andrade J., May J. Imaginary relish and exquisite torture: The elaborated intrusion theory of desire. Psychological Review 2005, 112(2):446-467.
62. Kavanagh D.J., Sitharthan G., Young R.M., Sitharthan T., Saunders J.B., Shockley N., Giannopoulos V. Addition of cue exposure to cognitive-behaviour therapy for alcohol misuse: A randomized trial with dysphoric drinkers. Addiction 2006, 101(8):1106-1116. Aug,.
63. Kelley A.E., Berridge K.C. The neuroscience of natural rewards: Relevance to addictive drugs. Journal of Neuroscience 2002, 22:3306-3311.
64. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzback R., et al. Comparing and combing naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry 2003, 60(1):92-99.
65. King A.C., Volpicelli J.R., Frazer A., O'Brien C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997, 129:15-22.
66. Krahn D.D., Bohn M.J., Henk H.J., Grossman J.L., Gosnell B. Patterns of urges during early abstinence in alcohol-dependent subjects. American Journal on Addictions 2005, 14:248-255.
67. Kranzler H.R., VanKirk J. Efficacy of naltrexone and acamprosate for alcoholism treat-ment: A meta-analysis. Alcoholism: Clinical and Experimental Research 2001, 25(9):1335-1341.
68. Kranzler H.R., Wesson D.R., Billot L. Naltexone depot for treatment of alcohol dependence: A mulitcenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research 2004, 28:1051-1059.
69. Kranzler H.R., Armeli S., Feinn R., Tennen H. Targeted naltrexone treatment mod-erates the relations between mood and drinking behavior among problem drinkers. Journal of Consulting and Clinical Psychology 2004, 72:317-327.
70. Kranzler H.R., Armeli S., Tennen H., Blomqvist O., Oncken C., Petry N., Feinn R. Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology 2003, 23:294-304.
71. Kratzer U., Schmidt W.J. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neuroscience Letters 1998, 252:53-56.
72. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 2001, 345(24):1734-1739.
73. Kuntze M.F., Stoermer R., Mager R., Roessler A., Mueller S.F., Bullinger A.H. Immersive virtual environments in cue exposure. CyberPsychology and Behavior 2001, 4(4):497-501.
74. 2 dopamine receptor A (1) allele and opioid dependence: Association with heroin use and response to methadone treatment. American Journal of Medical Genetics 2000, 96:592-598.
75. 2 dopamine receptor A1 allele. Nature Medicine 1995, 1:337-341.
76. Lee J., Lim Y., Graham S.J., Kim G., Wiederhold B.K., Wiederhold M.D., Kim I.Y., Kim S.I. Nicotine craving and cue exposure therapy by using virtual environments. CyberPsychology and Behavior 2004, 7:705-713.
77. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk L.H., Pinto A., Kucharski S., Krishnan S., Niaura R., Epstein L.H. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology 2003, 22:541-548.
78. Lowe M.R., Green L., Kurtz M.S., Ashenberg Z.S., Fisher E.B.Jr. Self-initiated, cue extinction and covert sensitization procedures in smoking cessation. Journal of Behavioral Medicine 1980, 3:357-372.
79. MacKillop J., Lisman S.A. Improving generalizability of extinction to alcohol cues via exposure in multiple contexts. Alcoholism: Clinical and Experimental Research 2005, 29:152A. Suppl.
80. Marlatt G.A. Cue exposure and relapse prevention in the treatment of addictive behaviors. Addictive Behaviors 1990, 15(4):395-399.
81. Marlatt G.A., Gordon J.R. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors 1985, New York:Guilford.
82. Maude-Griffin P., Tiffany S.T. Production of smoking urges through imagery: The impact of affect and smoking abstinence. Experimental and Clinical Psychopharmacology 1996, 4:198-208.
83. May J., Andrade J., Panabokke N., Kavanagh D. Images of desire: Cognitive models of craving. Memory 2004, 12:447-461.
84. McCaul M.E., Monti P.M. Research priorities for alcoholism treatment. Recent Developments in Alcoholism 2003, 16:405-414.
85. McCaul M.E., Wand G.S., Eissenberg T., Rohde C.A., Cheskin L.J. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropyschopharmacology 2000, 22(5):480-492.
86. McLellan A.T., Lewis D., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. The Journal of the American Medical Association 2000, 284(13):1689-1695.
87. McGeary J., Monti P.M., Rohsenow D.J., Tidey J.W., Swift R.M., Miranda R. Genetic Moderators of naltrexone's effect's on alcohol cue reactivity. Alcoholism: Clinical and Experimental Research 2006, 30:1288-1296.
88. Miranda R., Monti P.M., Swift R., MacKillop J., Tidey J., Gwaltney C., Rohsenow D. December) . Dose-dependent effects of topiramate on alcohol cue reactivity and the sub-jective effects of drinking: Preliminary data [Abstract]. Neuropsychopharmacology 2005, 30(Suppl.1):S152.
89. Moolchan E.T., Robinson M.L., Ernst M., Cadet J.L., Pickworth W.B., Heishman S.J., Schroeder J.R. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005, 115:407-414.
90. Monterosso J.R., Flannery B.A., Pettinati H.M., Oslin D.W., Rukstalis M., O'Brien C.P., Volpicelli J.R. Predicting treatment response to naltrexone: The influence of craving and family history. American Journal on Addictions 2001, 10:258-268.
91. Monti P.M., Abrams D., Kadden R., Cooney N. Treating Alcohol Dependence: A Coping Skills Training Guide 1989, Guilford Press, New York.
92. Monti P.M., Kadden R., Rohsenow D.J., Cooney N., Abrams D. Treating Alcohol Dependence: A Coping Skills Training Guide 2002, Guilford Press, New York.
93. Monti P.M., Miranda R., Nixon K., Sher K.J., Swartzwelder H.S., Tapert S.F., White A., Crews F.T. Adolescence: Booze, Brains and Behavior. Alcoholism: Clinical and Experimental Research 2005, 29:207-220.
94. Monti P.M., Niaura R., Abrams D.B. Ongoing research and future directions. The Tobacco Dependence Treatment Handbook: A Guide to Best Practices 2003, New York: Guilford. D.B. Abrams, R. Niaura, R.A. Brown, K.M. Emmons, M.G. Goldstein, P.M. Monti (Eds.).
95. Monti P.M., Rohsenow D.J., Hutchinson K.E. Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction 2000, 95:S229-S236.
96. Monti P.M., Rohsenow D.J., Hutchinson K.E., Swift R.M., Mueller T.I., Colby S.M., Kaplan G.B. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcoholism: Clinical and Experimental Research 1999, 23(8):1386-1394.
97. Monti P.M., Tidey J., Czachowski C.L., Grant K.A., Rohsenow D.J., Sayette M., Maners N., Pierre P. Building bridges: The transdisciplinary study of craving from the animal lab to the lamppost. Alcoholism: Clinical and Experimental Research 2004, 8:279-287.
98. Monti P.M., Rohsenow D.J., Rubonis A.V., Niaura R.S., Sirota A.D., Colby S.M., Goddard P., Abrams D.B. Cue exposure with coping skills treatment for male alcoholics: A prelimi-nary investigation. Journal of Consulting and Clinical Psychology 1993, 61:1011-1019.
99. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I., Brown R.A., Gordon A., Abrams D.B., Niaura R.S., Asher M.K. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcoholism: Clinical and Experimental Research 2001, 25:1634-1647.
100. Myrick H., Anton R.F., Li X., Henderson S., Drobes D., Voronin K., George M.S. Differential brain activity in alcoholics and social drinkers to alcohol cues. Neuropsychopharmacology 2004, 29:393-402.
101. Niaura R., Abrams D.B., Demuth B., Pinto R., Monti P.M. Reactivity to smoking-related stimuli and early relapse to smoking. Addictive Behaviors 1989, 14(4):419-428.
102. Niaura R., Abrams D., Monti P.M., Pedraza M. Reactivity to high risk situations and smoking cessation outcome. Journal of Substance Abuse 1989, 1(4):393-405.
103. Niaura R., Abrams D.B., Shadel W.G., Rohsenow D.J., Monti P.M., Sirota A.D. Cue exposure treatment for smoking relapse prevention: A controlled clinical trial. Addiction 1999, 94(5):685-695.
104. O'Brien C.P. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. American Journal of Psychiatry, 2005, 162(8):1423-1430.
105. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R. Integrating systematic cue exposure with standard treatment in recovering drug dependent patients. Addictive Behaviors 1990, 15(4):355-365.
106. Olive M.F., Nannini M.A., Ou C.J., Koenig H.N., Hodge C.W. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. European Journal of Pharmacology 2002, 437:55-61.
107. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 1992, 49(11):881-887.
108. O'Malley S.S., Krishnan S.S., Farren C., Sinha R., Kreek M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortial axis. Psychopharmacology 2002, 160(1):19-29.
109. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., O'Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. Journal of Substance Abuse Treatment 1999, 16(2):163-167.
110. Panabokke N., May J., Eade D., Andrade J., Kavanagh D. Visual imagery tasks suppress craving for cigarettes. Unpublished manuscript, 2004, University of Sheffield, Sheffield,, England.
111. Payne T.J., Rychtarik R.G., Rappaport N.B., Smith P.O., Etscheidt M., Brown T.A., Johnson C.A. Reactivity to alcohol-relevant beverage and imaginal cues in alcoholics. Addictive Behaviors 1992, 17:209-217.
112. Perkins K.A., Lerman C., Keenan J., Fonte C., Coddington S. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers. Nicotine and Tobacco Research 2004, 6(3):501-507.
113. Petrakis I.L., Poling J., Levinson C., Nich C., Carroll K., Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry 2005, 57(10):1128-1137.
114. Powell J., Gray J.A., Bradley B.P., Kasvikis Y., Strang J., Barrett L., Marks I. The effects of exposure to drug-related cues in detoxified opiate addicts: A theoretical review and some new data. Addictive Behaviors 1990, 15(4):339-354.
115. Raw M., Russell M. A Rapid smoking, cue exposure and support in the modification of smoking. Behaviour Research and Therapy 1980, 18(5):363-372.
116. Rauhut A.S., Thomas B.L., Ayres J.B. Treatments that weaken Pavlovian conditioned fear and thwart its renewal in rats: Implications for treating human phobias. Journal of Experimental Psychology: Animal Behavioral Processes 2001, 27:99-114.
117. Rinn W., Desai N., Rosenblatt H., Gastfriend D.R. Addiction denial and cognitive dysfunction: A preliminary investigation. Journal of Neuropsychiatry and Clinical Neurosciences 2002, 14:52-57.
118. Rigotti N.A. Treatment of tobacco use and dependence. New England Journal of Medicine 2002, 346(7):506-512.
119. Rohsenow D.J. What place does naltrexone have in the treatment of alcoholism?. CNS Drug Reviews 2004, 18(9):547-560.
120. Rohsenow, D. J., Miranda, R., McGeary, J. E., & Monti, P. M. (submitted). Family history and antisocial traits, not age of onset, moderate naltrexone's effect.
121. Rohsenow D.J., Monti P.M., Hutchison K.E., Swift R.M., Colby S.M., Kaplan G.B. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. Journal of Abnormal Psychology 2000, 109(4):738-742.
122. Rose J.E., Behm F.M., Westman E.C., Coleman R.E. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug and Alcohol Dependence 1999, 56:99-107.
123. Rubio G., Ponce G., Jimenez-Arriero M.A., Palomo T., Manzanares J., Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 2004, 37:37-40.
124. Rubio G., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero A., Hoenicka J., Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone?. Alcohol and Alcoholism 2005, 40(3):227-233.
125. Shiffman S., Engberg J., Paty J.A., Perz W., Gnys M., Kassel J.D., Hickcox M. A day at a time: Predicting smoking lapse from daily urge. Journal of Abnormal Psychology 1997, 106:104-116.
126. Shiffman S., Paty J.A., Gnys M., Kassel J.D., Hickcox M. First lapses to smoking: Within-subjects analysis of real time reports. Journal of Consulting and Clinical Psychology 1996, 64:366-379.
127. Shiffman S., Shadel W.G., Niaura R., Khayrallah M.A., Jorenby D.E., Ryan C.F., Ferguson C.L. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology 2003, 166(4):345-350.
128. Sobell M.B., Sobell L.C. Stepped care as a heuristic approach to the treatment of alcohol problems. Journal of Consulting and Clinical Psychology 2000, 68:573-579.
129. Swift R.M. Drug therapy for alcohol dependence. The New England Journal of Medicine 1999, 340:1482-1489.
130. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry 1994, 151(10):1463-1467.
131. Tiffany S.T., Cox L.S., Elash C.A. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. Journal of Consulting and Clinical Psychology 2000, 68(2):233-240.
132. Tucker J.A., Vuchinich R.E., Rippens P.D. Predicting natural resolution of alcohol-related problems: A prospective behavioral economic analysis. Experimental and Clinical Psychopharmacology 2002, 10:248-257.
133. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treat-ment of alcohol dependence. Archives of General Psychiatry 1992, 49(11):876-880.
134. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and Alcohol dependence: Role of subject compliance. Archives of General Psychiatry 1997, 54:737-742.
135. Volpicelli J.R., Watson N.T., King A.C., Sherman C.E., O'Brien C.P. Effect of naltrexone on alcohol "high" in alcoholics. American Journal of Psychiatry, 1995, 152(4):613-615.
136. Waters A.J., Shiffman S., Sayette M.A., Paty J.A., Gwaltney C.J., Balabanis M.H. Cue-provoked craving and nicotine replacement therapy in smoking cessation. Journal of Consulting and Clinical Psychology 2004, 72(6):1136-1143.
137. Weinstein A., Feldtkeller B., Feeney A., Lingford-Hughes A., Nutt D. A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addiction Biology 2003, 8:229-232.
138. Wertz J.A., Sayette M.A. A review of the effects of drug abuse opportunity on self-reported urge. Experimental and Clinical Psychopharmacology 2001, 9:3-13.
139. West R.J., Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: A systematic review. Psychopharmacology 2001, 155(2):115-122.
140. Westerberg V.S. Constituents of craving in a clinical alcohol sample. Journal of Substance Abuse 2000, 12:415-423.
141. White W.L. Slaying the Dragon: The History of Addiction Treatment and Recovery in America 1998, Bloomington, IL: Chestnut Health Systems.
142. Wiederhold B.K., Wiederhold M.D. Lessons learned from 600 virtual reality sessions. Cyberpsychology & Behavior 2000, 3:393-400.
143. Wiederhold B.K., Wiederhold M.D. Virtual Reality Therapy for Anxiety Disorders: Advances in Evaluation and Treatment 2005, Washington,DC: American Psychological Association.
144. Wise R.A. The neurobiology of craving: Implications for the understanding and treatment of addiction. Journal of Abnormal Psychology 1988, 97:118-132.
145. Woodruff S.I., Edwards C.C., Conway T.L., Elliott S.P. Pilot test of an internet virtual world chat room for rural teen smokers. Journal of Adolescent Health 2001, 29:239-243.